26 . 10 .2023
Press release
Galderma phase III data published in The New England Journal of Medicine: full Olympia 2 trial results demonstrate nemolizumab’s rapid onset of action in patients with prurigo nodularis
13 . 10 .2023
Press release
Galderma unveils bold ambition in neuromodulation at Liquid Live event
11 . 10 .2023
Press release
Galderma @ EADV 2023: phase III trials demonstrate nemolizumab’s efficacy and rapid onset of action in atopic dermatitis and prurigo nodularis
04 . 10 .2023
Press release
EADV 2023: Galderma to present new data showcasing its continued leadership in dermatology
02 . 10 .2023
Press release
Galderma announces progress with RelabotulinumtoxinA regulatory submissions
29 . 07 .2023
Press release
Galderma reiterates its commitment to commercialize and continue developing the broadest Injectable Aesthetics portfolio on the market, following Ipsen's recent announcement
27 . 07 .2023
Press release
Galderma achieves record 2 B USD net sales for a six-month period in H1 2023, as it continues to demonstrate leading execution and innovation capabilities in dermatology
04 . 07 .2023
Press release
Galderma @ WCD 2023: late-breaking phase III results for nemolizumab monotherapy in prurigo nodularis show a significant proportion of itch-free patients by week 4
28 . 06 .2023
Press release
WCD 2023: Galderma to present extensive data demonstrating enduring commitment to delivering innovative solutions in dermatology
26 . 06 .2023
Press release
Galderma raises approximately USD 1 billion for newly issued shares in a private placement round